Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06115603 · ClinicalTrials.gov registry record · Phase 2
The Effects of Cannabigerol on Attention-Deficit/Hyperactivity Disorder
A Phase 2 study of Attention Deficit Hyperactivity Disorder, sponsored by University of Arkansas, Fayetteville.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 76
- Enrollment target
- 1
- Study location
NCT06115603: Recruiting Phase 2 study of Attention Deficit Hyperactivity Disorder, sponsored by University of Arkansas, Fayetteville.
NCT06115603 is a Phase 2 study of Attention Deficit Hyperactivity Disorder that is actively recruiting participants, run by University of Arkansas, Fayetteville. The registered enrollment target is 76 participants, below the 216-participant average among 102 other Attention Deficit Hyperactivity Disorder trials with a reported enrollment target (65% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06115603, a Phase 2 study of Attention Deficit Hyperactivity Disorder, is actively recruiting participants, sponsored by University of Arkansas, Fayetteville.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 76 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to evaluate the effects of Cannabigerol (CBG) on indicators of Attention-Deficit/Hyperactivity Disorder (ADHD) in a sample of participants indicating/reporting symptoms associated with ADHD. The main question it aims to answer is: Does CBG reduce ADHD-related indicators relative to placebo? Participants will administer an acute dose of placebo or 80mg CBG and complete outcome measures at 45 minutes and 75 minutes. Daily surveys to monitor safety will be administered for one week following administration.
Primary Outcome
A computerized task that measures response inhibition.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Cannabigerol
Study Locations (1)
Arkansas
- University of Arkansas - Fayetteville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2024-12-14 |
| Est. Completion | 2025-12 |
| Phase | Phase 2 |
What NCT06115603 shows while recruiting
NCT06115603 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 76 participants, a relatively small participant target, below the 216-participant average among 102 other Attention Deficit Hyperactivity Disorder trials with a reported enrollment target (65% lower).
The record links to 1 condition, with Attention Deficit Hyperactivity Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06115603 reports a single indexed study location in Arkansas.
Frequently Asked Questions
What is clinical trial NCT06115603 about?
NCT06115603 is a clinical study titled "The Effects of Cannabigerol on Attention-Deficit/Hyperactivity Disorder". The goal of this clinical trial is to evaluate the effects of Cannabigerol (CBG) on indicators of Attention-Deficit/Hyperactivity Disorder (ADHD) in a sample of participants indicating/reporting symptoms associated with ADHD. The main question it aims to answer is: Does CBG reduce ADHD-related indic...
What is the current status of trial NCT06115603?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 76 participants. The study started on 2024-12-14. Estimated completion is 2025-12.
What conditions does trial NCT06115603 study?
This clinical trial studies the following conditions: Attention Deficit Hyperactivity Disorder.
What interventions are being tested in trial NCT06115603?
The interventions under investigation include: Placebo (OTHER), Cannabigerol (DRUG).
Who is sponsoring clinical trial NCT06115603?
This trial is sponsored by University of Arkansas, Fayetteville, which has 25 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06115603 being conducted?
This trial has 1 study location across Arkansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Attention Deficit Hyperactivity Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06115603's enrollment target sits among peer trials
76 50th of 102 higher than 53 of 102 other Attention Deficit Hyperactivity Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Attention Deficit Hyperactivity Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
COMT Inhibition Among Individuals With Comorbid AUD/ADHD
RECRUITING · Phase 2
-
Acute Effects of Stimulant Medication in College Students With ADHD
RECRUITING · Phase 2
-
Preschool Supplement to Clonidine in ADHD (Kiddie-CAT)
COMPLETED · Phase 2
-
Study of the Safety and Efficacy of OPC-34712 as a Complementary Therapy in the Treatment of Adult Attention Deficit/Hyperactivity Disorder
COMPLETED · Phase 2
-
Dose-Finding Study to Evaluate the Efficacy and Safety of Modafinil as Treatment for Adults With ADHD
COMPLETED · Phase 2
-
Study of Droxidopa Treatment in Adults With Attention Deficit Hyperactivity Disorder With Co-administration of Carbidopa
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02615184 · 76 participants · Phase 2
A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old
- NCT02821741 · 76 participants · NA
Effects of External Ear Stimulation on Pain Perception and Mood
- NCT03019757 · 76 participants
Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease
- NCT03353584 · 76 participants · NA
Effect of Virtual Reality Technology for Pain Management of Vaso-Occlusive Crisis in Patients With Sickle Cell Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI